Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The NGAL Test™ As An Aid in the Risk Assessment for AKI Stage II and III in an Intensive Care Population

NCT03057457 is registered in ClinicalTrials.gov with BioPorto Diagnostics as lead sponsor.

NCT NCT03057457
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03057457 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The NGAL Test™ As An Aid in the Risk Assessment for AKI Stage II and III in an Intensive Care Population
Lead sponsor
BioPorto Diagnostics
Phase
Observational
Overall status
Unknown status
Start date
March 31, 2017
Completion date
February 28, 2018
Enrollment
530 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

kidney injury